Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology Times
(Image credit: AdobeStock/J Bettencourt) In conversation with Sydney M. Crago, Managing Editor of Ophthalmology Times, David R. Lally, MD, spoke about his presentation at the 2025 Retina Society meeting, which highlighted the results from the ARCHER trial (NCT04656561) of ANX007…
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial | Ophthalmology Times
Image credit: AdobeStock/MrAshi On September 4, 2025, Merck and EyeBio announced that the companies have initiated the Phase 2b/3 BRUNELLO trial (NCT06571045) to evaluate the candidate MK-3000, formerly known as EYE103 for the treatment of patients with diabetic macular edema…
Heterogeneous Ocular Biomarkers May Predict Sjögren’s Disease Extraocular Features | Ophthalmology Times
(Image Credit:AdobeStock) A study of the ocular features of Sjogren’s disease reported the heterogeneity of the disorder’s ocular presentations.1 The authors, led by research fellow Drew C. Baeza, MD, and associates, reported “distinct associations between specific dry eye and the…
Intravitreal complement inhibitor treatment for GA viewed favorably by patients | Ophthalmology Times
(Image Credit: AdobeStock) A new British study reported that treatment with intravitreal complement inhibitors (IVCIs) for geographic atrophy (GA) was viewed favorably by patients if the treatment was thought to impart visual benefits,1 according to first author Christiana Dinah, BSc,…
Chronic nAMD With Cataract Complications: Visual Stabilization Through Sequential Anti-VEGF Strategies | Ophthalmology Times
Treatment-Resistant Retinal Disease Management With Sequential Anti-VEGF Strategies This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported by pharmacokinetic modeling from 17 aflibercept trials involving 2700 individuals. The data demonstrates that aflibercept 8 mg exhibits 34.4%…
DME Management With Transition to High-Dose Aflibercept Following Suboptimal Response to Standard Anti-VEGF Therapy | Ophthalmology Times
DME Management With High-Dose Aflibercept Summary This presentation discusses DME management, focusing on transitioning to high-dose aflibercept following suboptimal responses to standard anti-VEGF therapy. The session was part of a Case-Based Roundtable meeting held in conjunction with the American Society…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…
Researchers assess atropine and cyclopentolate for detecting premyopia in young children | Ophthalmology Times
(Image Credit: AdobeStock) A comparison of 2 cycloplegic agents, atropine and cyclopentolate, in preschool children for cycloplegia found that atropine was associated with less myopic refraction compared with cyclopentolate and may potentially avoid the overestimation of premyopia prevalence,1 reported first…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD, PhD, introduced the Fight Retinal Blindness! Project, a comprehensive registry tracking VEGF inhibitor eye injection outcomes since 2007. Spanning 20 countries with 150 active practitioners, the project uniquely…